Insomnia Market Strategic Analysis and Research Outlook 2031
Insomnia Market Strategic Analysis and Research Outlook 2031
Blog Article
The global insomnia market, valued at US$ 3.8 billion in 2022, is projected to reach US$ 6.4 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2031. Insomnia therapeutics include prescription medications (e.g., benzodiazepines, non-benzodiazepines), over-the-counter (OTC) sleep aids, cognitive behavioral therapy (CBT-I), and emerging digital therapeutics. This article explores the market dynamics, key drivers, challenges, and opportunities shaping the insomnia market through 2031, highlighting its role in addressing a growing global sleep disorder burden.
Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20246
Market Overview
The insomnia market encompasses treatments for sleep disorders characterized by difficulty falling or staying asleep, affecting millions globally. Valued at US$ 3.8 billion in 2022, the market is expected to grow at a CAGR of 6.0% from 2023 to 2031, reaching US$ 6.4 billion by 2031. Growth is driven by increasing insomnia prevalence, advancements in pharmacological and non-pharmacological therapies, and rising awareness, particularly in North America, Europe, and Asia-Pacific.
Key Drivers of Growth
Rising Prevalence of Insomnia
Insomnia is increasingly common due to stress, lifestyle changes, and comorbidities like anxiety and depression, affecting urban populations in the U.S., Europe, and China. This drives demand for both prescription and OTC treatments.
Advancements in Treatment Options
Newer medications, such as orexin receptor antagonists (e.g., suvorexant) and dual orexin receptor antagonists (DORAs), offer improved safety profiles over traditional benzodiazepines, boosting adoption in North America and Europe.
Growth in Digital Therapeutics
Digital platforms offering CBT-I, sleep tracking, and personalized interventions are gaining traction, particularly in tech-savvy markets like the U.S. and Japan, with a projected market value of US$ 5.16 billion by 2031 for digital insomnia therapeutics alone.
Increasing Awareness and Diagnosis
Public health campaigns and improved diagnostic tools are reducing stigma and increasing treatment-seeking behavior, particularly in Asia-Pacific and Europe, where sleep health awareness is rising.
Top Companies:
Paratek Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
copyright Inc.
Sanofi S.A
Merck & Co., Inc.
Viatris Inc.
Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/insomnia-market.html
Challenges and Barriers
High Costs of Advanced Therapies
Novel medications and digital therapeutics are expensive, limiting access in developing regions like Africa and parts of Asia-Pacific, where affordability remains a barrier.
Side Effects of Pharmacological Treatments
Traditional drugs like benzodiazepines, which dominated the U.S. market in 2024, are associated with dependency and cognitive side effects, reducing patient compliance globally.
Regulatory and Reimbursement Challenges
Stringent FDA and EMA regulations for new insomnia drugs and limited insurance coverage for digital therapeutics slow market entry, particularly in emerging markets like India and Brazil.
Market Valuation Discrepancies
Significant variability in reported market sizes (e.g., US$ 5.44 billion in 2024 per vs. US$ 3.8 billion in 2022 per) suggests differences in scope (e.g., including sleep aids or broader sleep disorders), complicating forecasting.
Regional Insights
North America leads the insomnia market, driven by the U.S., due to high prevalence, advanced healthcare infrastructure, and adoption of novel therapies, though with a lower CAGR of 3.8% from 2025-2030. Europe, particularly Germany and the UK, follows, supported by robust reimbursement and growing CBT-I adoption. Asia-Pacific, led by China and Japan, is a fast-growing region due to rising stress-related insomnia and healthcare investments. Emerging markets in Latin America and Africa show potential but face cost and awareness barriers.
Future Opportunities
Digital and Non-Pharmacological Therapies: Expanding CBT-I platforms and wearable sleep tech could address unmet needs, particularly in North America and Asia-Pacific.
Emerging Market Growth: Improving healthcare access in India and Brazil could unlock demand for affordable OTC and generic treatments.
Personalized Medicine: Biomarkers and genetic profiling for tailored insomnia treatments could gain traction in the U.S. and Europe.
Public-Private Partnerships: Collaborations to promote sleep health awareness could drive demand in Asia-Pacific and Latin America.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Report this page